Navigation Links
Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
Date:12/10/2007

ATLANTA, Dec. 10 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL), today reported phase 1 data from an ongoing phase 1 trial of XL019 in patients with myelofibrosis, a myeloproliferative disorder (MPD). XL019 is an investigational small molecule that selectively inhibits the tyrosine kinase JAK2, one of four JAK family members activated in response to cytokines and hematopoietic growth factors. JAK2 is inappropriately activated in the majority of MPD patients and is deregulated in a number of solid tumors, including certain subtypes of lymphoma. Dr. Srdan Verstovsek from the M. D. Anderson Cancer Center, Houston, TX today presented data from an ongoing phase 1 study in an oral presentation session (Abstract #553) at the American Society of Hematology 49th Annual Meeting and Exposition, which is taking place in Atlanta, December 8th-11th.

"We are very encouraged by the results from this ongoing trial that show rapid decrease in spleen size and relief of disease-related symptoms at low doses of XL019. XL019 is a highly selective inhibitor of JAK2 that may have the potential to provide important benefit for patients with myeloproliferative disorders and other diseases driven by JAK2," said Michael Morrissey, Ph.D., president of research and development at Exelixis. "We believe that JAK2 is a critical target in myeloproliferative disorders, and effective inhibition of JAK2 may directly translate into clinical benefit. The strong linkage of JAK2 to MPDs provides a potentially quick route to market, with potential for additional opportunities in larger commercial indications. We are planning to initiate pivotal trials of XL019 in myelofibrosis patients in 2008."

Trial Design

The phase 1 dose escalation study of XL019 is ongoing in subjects with primary myelofibrosis (MF) and post-polycythemia vera/essential thrombocythemia MF. To date nine patients have been enrolled. The primary objective of this study is to determine the safety and tol
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. GlaxoSmithKline Accelerates Review of Exelixis XL880
2. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
3. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
6. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
7. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
10. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
11. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... July 2, 2015 Releases of ... Aedes aegypti , , reduced the dengue ... Brazil by 95%, well below the modelled ... http://photos.prnewswire.com/prnh/20150630/227348LOGO) , The journal PLOS Neglected Tropical ... Oxitec,s genetically engineered mosquitoes. The results showed that in ...
(Date:7/2/2015)... 2015 According to a new market ... Stimulation, Spinal Cord Stimulation, Transcranial Magnetic Stimulation), Application (Depression, Parkinson,s, ... 2020", published by MarketsandMarkets, the global Neuromodulation Market is estimated ... $6.20 Billion by 2020, at a CAGR of 11.2% during ... 4 market data T ables and ...
(Date:7/2/2015)... 25, 2015 Research and Markets( http://www.researchandmarkets.com/research/nlfg34/cancer ... by Technology, Imaging and by Application - Forecast to 2020" ... is expected to reach $13.1 Billion in 2020 from an estimated ... The market is dominated by North America ... , and Rest of the World (RoW). The cancer diagnostics ...
Breaking Medicine Technology:Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 3Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4Global Cancer Diagnostics Market Report 2015 - Technology, Imaging and by Applications Forecasts to 2020 for the $13 Billion Industry 2
... Oramed,Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), ... that its abstract, entitled "Open,Label Study to ... of Five Oral Insulin Formulations in Healthy,Subjects," ... upcoming 44th Annual,Meeting of the European Association ...
... Industry Leader with Strong Clinical Research Relationships and ... Organizations to Lead Commercialization, SANTA CLARA, Calif., ... a cardiac diagnostic and services company, today,announced that ... president. Mr.,Renz will oversee the Company,s commercialization effort, ...
Cached Medicine Technology:Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome) 2Vincent W. Renz Joins NewCardio as President 2Vincent W. Renz Joins NewCardio as President 3Vincent W. Renz Joins NewCardio as President 4
(Date:7/3/2015)... ... 2015 , ... First Choice Emergency Room , the largest network of ... the new Medical Director of its Frisco facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:7/2/2015)... VA (PRWEB) , ... July 02, 2015 , ... sweetFrog ... Albany, Mississippi. The opening is the first sweetFrog store located in Mississippi. The premium ... growing companies in 2014. , The store, located at 104 Railroad Avenue, New Albany, ...
(Date:7/2/2015)... ... July 02, 2015 , ... When Walker Parking Consultants ... University of Minnesota, they knew it would save the university energy and maintenance ... choice: the total energy savings after installation was an impressive 89 percent, which ...
(Date:7/2/2015)... ... July 02, 2015 , ... As Americans celebrate the Fourth of July outdoors ... is on the rise. July is UV Safety Month, and physicians at American Family ... of getting skin checks. Experts say most skin cancers can be found early with ...
(Date:7/2/2015)... ... July 02, 2015 , ... ActiveBunch.com recently launched as a ... fitness. Built to function as a lifestyle community, Active Bunch allows users to connect ... network, meet, and participate in discussions or group events. , The spokesperson for ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:sweetfrog Opens First Location in Mississippi 2Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2Health News:Local Physicians Warn of Holiday Health Hazards 2Health News:Local Physicians Warn of Holiday Health Hazards 3Health News:Local Physicians Warn of Holiday Health Hazards 4Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2
... West Bengal was first refused treatment by government hospitals ... human rights group intervened to unshackle him, reports said ... by the Association for the Protection of Democratic Rights ... North 24 Parganas district freed., ,Debnath had developed ...
... Watch had explored the physiology// of hot flashes experienced by ... flashes are well known to most menopausal women—and to many ... tend to come on suddenly and last from one to ... to a feeling of being on fire. , ,Although ...
... authorities are pouring cold water on hopes for a new drug ... and Drug Administration (FDA) wants more studies to be done on ... find out what long-term side effects the drug may induce, the ... "female Viagra" as it promises to restore healthy sexual appetites to ...
... pollution levels may have an increased chance of a heart ... ,The research done by scientists from Loma Linda University had ... Environmental Health Perspectives. Their research findings suggest that the rate ... more if they happen to live in areas that have ...
... ,Chennai's Adyar Cancer Institute director Dr.V. Shanta is among ... was awarded the prize for public service and her "untiring ... and compassion for the study and treatment of cancer// in ... She has also won a number of national and international ...
... from kidney diseases may have increased risk of death ... from Johns Hopkins University School of Medicine have found ... peritoneal dialysis over hemodialysis increases their risk of dying ... published in the journal Annals of Internal Medicine online ...
Cached Medicine News:Health News:Insight for Hot Flashes In Postmenopausal Women 2Health News:FDA Diminish Hopes On ‘Female Viagra 2Health News:FDA Diminish Hopes On ‘Female Viagra 3Health News:Air Pollution Increases Risk For Heart Disease In Women 2Health News:Magsaysay Award for Dr.Shanta from Chennai Cancer Institute 2Health News:Choice Of Treatment Increases Risk Of Death In Kidney Disease 2
3 mm forked angled blades. Blade spread 7 mm. Flat serrated handle with polished finish. Overall length: 4.8 inches....
5 mm curved hook with markings at 14 mm and 20 mm from tip. Flat serrated handle with polished finish. Overall length: 4.7 inches....
Small bulbous tip with flat sides. Flat serrated handle with polished finish. Overall length: 5.1 inches....
This teardrop-shaped tip with multi-angled shaft is ideal for the "Miracle Multiple-Cut" technique and is used for dividing and manipulating nucleus material from all directions in the capsule. Round...
Medicine Products: